Once thriving, the influenza vaccine business in the United States is on a dramatic downward trend. Only 157 million flu shots have been distributed so far during the 2023-2024 flu season.
This data indicates a 19% decrease for the 2020-2021 season when 194 million flu shots were distributed.
With the influenza vaccine's efficacy hovering around 50%, the protective benefits people receive cannot be the reason behind this sudden, negative trend.
Did Vaccine Mandates Decrease Flu Shots by 19%
Did Vaccine Mandates Decrease Flu Shots by 19%
Once thriving, the influenza vaccine business in the United States is on a dramatic downward trend. Only 157 million flu shots have been distributed so far during the 2023-2024 flu season.
This data indicates a 19% decrease for the 2020-2021 season when 194 million flu shots were distributed.
With the influenza vaccine's efficacy hovering around 50%, the protective benefits people receive cannot be the reason behind this sudden, negative trend.
Potential On-Demand Lyme Disease Protection
Tarsus Pharmaceuticals, Inc. has just announced positive topline results from the Phase 2a Carpo trial evaluating TP-05 (lotilaner). This novel, oral therapeutic candidate has shown remarkable effectiveness in preventing Lyme disease.
TP-05 is not U.S. FDA-approved but is believed to be the only non-vaccine, drug-based, preventative therapeutic in development designed to kill ticks before they transmit Lyme disease to people.
This vector-borne disease often goes undetected because ticks are not always noticed.